Newron H1 FY26 net loss widens to EUR 16.4 million; revenue drops 73.2% to EUR 3.2 million
Bitget2026/09/22 04:59- Newron posted H1 2026 revenue of EUR 3.19 million, down 73.2% from a year earlier.
- Net loss widened to EUR 16.37 million, swinging from a EUR 73,000 loss; R&D expenses more than doubled to EUR 14.55 million.
- Cash and other current financial assets rose to EUR 32.89 million at June 30, 2026, up 13.9% from Dec. 31, 2025.
- ENIGMA-TRS 1 screening completed in September; target enrollment of at least 600 patients is expected around mid-October, with topline 12-week data in Q1 2027.
- Following a Type A FDA meeting, Newron expects U.S. enrollment in ENIGMA-TRS 2 to resume in the near future, while enrollment continues outside the U.S.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
